Navigation Links
MDS Pharma Services Launches Next Generation Phase I Study Management System
Date:7/7/2008

Proprietary ClinQuick(R) system builds on a 15-year track record of

technical leadership in early clinical research

KING OF PRUSSIA, PA, July 7 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has launched the next generation of its proprietary ClinQuick(R) electronic system for Phase I study set-up, data capture, project tracking and personnel credential management. Aimed at improving client service, the new version of the ClinQuick(R) system extends a 15-year legacy of technical leadership in early clinical research. System enhancements include a more user-friendly interface, improved menu navigation and a more robust data platform. This new platform will enable faster and more flexible reporting and will ultimately allow clients to access their data via the internet.

"Since its implementation in 1993, ClinQuick(R) has been used successfully in more than 3,000 Phase I studies involving nearly 100,000 participants," said MDS Pharma Services President David Spaight. "Our investment to enhance the ClinQuick(R) system builds on that legacy of success and will allow us to meet growing client demand for early clinical research services while maintaining our leadership position in Phase I. This next-generation ClinQuick(R) system will further improve our ability to deliver high quality Phase I services on time."

About ClinQuick(R)

Designed and built by MDS Pharma Services for use in its Phase I clinical research centers, the fully integrated ClinQuick(R) system facilitates rapid data cleansing and client monitoring for seamless operation of both single and multi-site studies. ClinQuick(R) accelerates timelines, enables accurate direct data acquisition, and reduces costs by a third compared to traditional paper case report forms (CRFs) - the forms used by clients to collect and document data from each participating clinical research site. The system is fully CFR Part 11 compliant and can be used for study management and electronic data capture (EDC), either alone or in conjunction with a client-provided EDC system or paper CRFs. MDS Pharma Services offers one of the world's largest capacities for conducting early-phase clinical studies, with some 1,100 beds in five state-of-the-art clinical research facilities in North America and Europe.

About MDS Pharma Services

MDS Pharma Services is committed to delivering quality service on time. We offer a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With numerous facilities strategically located around the world, we apply advanced scientific and technological expertise throughout the drug discovery and development process - from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases IIb-IV), central lab and centralized cardiac services. For more information, visit our website at http://www.mdsps.com.

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 ... ... to connecting doctors and patients to provide information about cosmetic procedures, began updating ... now started to rewrite each of their published articles in order to feature ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Security Executive® (ISE®) Northeast Awards. , Awards include the Information Security Executive® ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... residents of Westchester County for over 24 years, recently hosted its sixth annual ... joined HOW for two remembrance ceremonies, each concluding with the release of Monarch ...
(Date:5/23/2016)... ... May 23, 2016 , ... Overweight and obesity in children can ... the budget, but most of all, it can be hard on the child carrying ... diet food—isn’t making a dint in childhood obesity statistics or making it easier for ...
(Date:5/23/2016)... ... May 23, 2016 , ... A team of cardiovascular surgeons ... the first in the region to use a groundbreaking new technology to provide ... Program partnered with AHN to introduce the technology to the Pittsburgh market. , ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... 19, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... for the treatment of grievous blood-based disorders with significant ... be presented in a poster session at the European ... Copenhagen . The presentations will include additional ... sickle cell disease (SCD), including 90-day data from a ...
(Date:5/19/2016)... , May 19, 2016  IBM,s (NYSE:   IBM )  ... study to identify drug candidates to cure Zika, a ... declared a global public health emergency. IBM ... with a computer or Android device to join the ... or money to help; they simply  run an app ...
(Date:5/18/2016)... 19, 2016 Global ... Report initially provides a basic overview of ... manufacturing technology, post which the report explores ... the market. Complete report on ... providing 8 company profiles and 98 tables ...
Breaking Medicine Technology: